Placabo

Phase 3Small molecule

AAllergopharma GmbH & Co. KG

Placabo is one of 40 small molecule programs targeting Sedation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConjunctivitisActive, not recruiting

Acute BronchitisActive, not recruiting

ConjunctivitisPhase 3

Active, not recruiting

Acute BronchitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Conjunctivitis

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

2 2

Neoral

Novartis

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Tobrex

VViatris Specialty LLC

Approved

1 5

Lotemax

BBausch & Lomb Incorporated

Approved

1 6

Prograf

VVeloxis Pharmaceuticals

Levaquin

Cytovene

EExela Pharma Sciences, LLC.

Phase 3

1 9

Decadron

AAspen Global Incorporated

Phase 3

1 10

Claritin

PPerrigo Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Sedation

NCT07166666

Clinical

Trials by Indication[1]

Conjunctivitis1 trial

2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma

Completed·AAllergopharma GmbH & Co. KG·Phase 3·NCT01353755·195 enrolled

Acute bronchitis1 trial

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

Completed·KKorea Arlico Pharm. Co., Ltd·Phase 2·NCT07061925·169 enrolled

Sedation1 trial

Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old)

Not yet recruiting·OOman Medical Speciality Board·N/A·NCT07166666·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Placabo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Placabo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Placabo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allergopharma GmbH & Co. KG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAllergopharma GmbH & Co. KG

Placabo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Conjunctivitis1 trial

Acute bronchitis1 trial

Sedation1 trial

References

Drug Info

Quick Facts

Related News